Related Experiment Videos
Immunization of young infants with Edmonston-Zagreb measles vaccine
1Division of Immunization, Centers for Disease Control, Atlanta, GA 30333.
Insights
The Edmonston-Zagreb measles vaccine shows high efficacy in infants under 9 months, matching the Schwarz vaccine's rates. Further studies are needed to confirm its potential for preventing measles in young infants in endemic regions.
Area of Science:
- Pediatrics
- Vaccinology
- Infectious Diseases
Background:
- Measles remains a significant threat in highly endemic areas.
- Current measles vaccination schedules typically begin at 9 months of age.
- The Schwarz vaccine is the widely used standard for measles prevention.
Purpose of the Study:
- To evaluate the efficacy of the Edmonston-Zagreb measles vaccine in infants younger than 9 months.
- To assess the potential of early measles vaccination for improved public health outcomes.
- To provide data supporting potential changes in global measles vaccination recommendations.
Main Methods:
- Subcutaneous administration of the Edmonston-Zagreb vaccine to infants under 9 months.
- Monitoring seroconversion rates in the vaccinated infant population.
- Comparison of seroconversion rates with the standard Schwarz vaccine administered at 9 months.
Main Results:
- High seroconversion rates observed with the Edmonston-Zagreb vaccine in infants under 9 months.
- Efficacy rates approached or equaled those of the Schwarz vaccine given at 9 months.
- Preliminary findings suggest the Edmonston-Zagreb vaccine is a promising alternative for early infant vaccination.
Conclusions:
- The Edmonston-Zagreb vaccine demonstrates potential for effective measles prevention in infants younger than 9 months.
- Further research is crucial to confirm these findings and address new questions before policy changes.
- Successful implementation could significantly impact measles control in high-risk populations.
Abstract:
Recently studies conducted in several countries using Edmonston-Zagreb vaccine administered subcutaneously to infants younger than 9 months of age have shown high seroconversion rates, approaching or equaling those routinely achieved at 9 months of age with the more widely used Schwarz vaccine. These results have raised expectations that the Edmonston-Zagreb vaccine can play an important role in helping to prevent measles in young infants in highly endemic areas. Because of the implications of changing the measles vaccine recommendations, vaccine advisory groups and vaccine manufacturers will require additional studies to confirm the preliminary findings and to answer new questions which have been raised. The needed data will probably be collected over the next year or two in studies already under way or being planned in the hope that a more effective vaccine for young infants can be introduced before the end of this decade.